Skip to main content

Table 6 Glance over the ability of different assays in distinguishing the radiosensitivity level among breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy complication

From: Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays

  BC cases vs Healthy controls Healthy BRCA1 mutation carriers vs Healthy controls Healthy BRCA2 mutation carriers vs Healthy controls Healthy BRCA1/2 mutation carriers vs Non-carrier subjects from BRCA1/2 families BC with BRCA1/2 mutation vs BC W/O BRCA1/2 mutation BRCA2 vs BRCA1 Radiotherphy Complication
G2 MN assay - - + + - + + + + - +   + - +
G0 MN assay + + + + + + + - - - -   - + -
G2 chromosomal assay + + + + + + + + - + +   -   - -
G0 chromosomal assay + +       
Comet assay + - - + - - - - -    + -
H2AX, P53bp biomarkers + + + -      + + - +
  1. BC breast cancer, MN micronucleus, W/O without
  2. + the technique was able to detect the more radiosensitive group
  3. - the technique failed to detect the more radiosensitive group